A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
Your participation in this trial could last up to 67 months, depending on your cancer type and how you and your tumor responds.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue
-Participants must be able to swallow capsules
-Participants must not have had more than 3 treatment regimens given after frontline initial therapy
-Participants must not have had prior allogeneic or solid organ transplant
-Participants must not have untreated tumor that has spread to the brain or spinal cord
-Participants must not have a serious active disease other than neuroblastoma
-Participants must not have a condition affecting absorption
-Participants must not have had prior aurora kinase inhibitor exposure
-Participants must not have a known allergy to the study treatment
-Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C